SOPHiA GENETICS has announced an expansion of its collaboration with AstraZeneca to enhance the detection and treatment of breast and prostate cancers. The partnership focuses on developing an optimized next-generation sequencing (NGS) solution that leverages SOPHiA GENETICS’s AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway. This pathway is crucial in regulating cell growth and survival, and its disruption is linked to various cancers. The companies have developed an NGS solution that deploys AI agents to analyze and detect genomic mutations across the full PTEN gene, aiming to improve the diagnosis and treatment of these cancers.
Also Read: Twist Bioscience Unveils Oncology DNA CGP Panel for Precision Medicine
A prototype of the enhanced solution has already demonstrated improved sensitivity in detecting complex mutations across the pathway. As part of the collaboration, SOPHiA GENETICS will roll out a Privileged Access Program to selected clinical laboratories specializing in breast and prostate cancer research to validate sensitivity in a real-world setting. A multi-center real-world evidence study is also planned to further test its effectiveness, with broader commercial availability expected in 2026. This initiative underscores the commitment of both companies to advancing precision medicine through AI-driven solutions.